• Explore /
  • Poster
  • / Zanidatamab, an anti-HER2 bispecific antibody, plus chemotherapy with/without tislelizumab as first-line treatment for patients with advanced HER2-positive breast cancer or gastric/gastroesophageal junction adenocarcinoma: A phase 1B/2 trial-in-progress.

Zanidatamab, an anti-HER2 bispecific antibody, plus chemotherapy with/without tislelizumab as first-line treatment for patients with advanced HER2-positive breast cancer or gastric/gastroesophageal junction adenocarcinoma: A phase 1B/2 trial-in-progress.

Abstract Video & Slides Poster

Authors

null

Keun Wook Lee

Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, South Korea

Keun Wook Lee , Young-Hyuck Im , Keun Seok Lee , Jae Yong Cho , Do-Youn Oh , Hyun Cheol Cheol Chung , Yee Chao , Li-Yuan Bai , Chia Jui Yen , In-Ho Kim , Sang Cheul Oh , Chia-Chi Lin , Jin Wang , Xin Wang , Huiyan Li , Yen-Yang Chen , Yoon-Koo Kang

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

Antibodies

Clinical Trial Registration Number

NCT02892123

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr TPS2656)

DOI

10.1200/JCO.2021.39.15_suppl.TPS2656

Abstract #

TPS2656

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Do-Youn Oh

First Author: Keun Wook Lee

First Author: Keun-Seok Lee

First Author: Josep Tabernero